Please assess the completion status of the following clinical trial:

Trial Title: MIRACLE EF Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has diagnosis of chronic heart failure \> 90 days in duration~* Has left ventricular ejection fraction (LVEF) between 36% and 50%, inclusive, as documented at baseline or within 30 days prior to enrollment~* Is either: (a) NYHA Class III at enrollment or at baseline OR (b) NYHA Class II at enrollment or at baseline, with a documented hospitalization for HF in the 12 months prior to enrollment OR (c) NYHA Class II at enrollment or at baseline, without a documented hospitalization for HF in the prior 12 months, but with BNP ≥250 pg/ml or NT-proBNP ≥1000 pg/ml~* Has documented left bundle branch block (LBBB) with QRS ≥130ms at baseline or within 30 days prior to enrollment.~* Is in sinus rhythm at time of enrollment or at the baseline visit.~* Has had no additions to or subtractions from non-diuretic heart failure medical therapy within 30 days prior to enrollment~* Is on maximum tolerated (guideline) dosages of medications in ACC/AHA guidelines for HF, Ischemic Heart Disease, Hypertension and AF as appropriate.~* Has signed and dated the study informed consent.~* Is able to receive a pectoral CRT-P implant.~* Is expected to remain available for follow-up visits.~* Is willing and able to comply with the Clinical Investigation Plan.~Exclusion Criteria:~* Requires permanent cardiac pacing.~* Indicated for implantable cardioverter defibrillator (ICD), such as for secondary prevention of prior sudden cardiac arrest, related to prior history of ventricular tachycardia and/or ventricular fibrillation.~* Less than 18 years of age, or under a higher minimum age requirement as defined by local law.~* Unstable angina or an acute MI within 40 days prior to enrollment.~* Coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) within the 90 days prior to enrollment.~* Chronic (permanent) atrial arrhythmias. Chronic (permanent) atrial arrhythmias are defined as cases of long-standing atrial fibrillation (e.g., greater than 1 year) in which cardioversion has not been indicated or attempted.~* Cardioversion for atrial fibrillation within 30 days prior to enrollment.~* Treatable pericardial constraint within 30 days prior to enrollment.~* Restrictive (infiltrative) cardiomyopathies, such as amyloidosis, sarcoidosis, or hemochromatosis.~* Enrolled in a concurrent study, with the exception of a study-manager approved study that is strictly observational in nature and does not confound the results of this study (e.g. registries).~* Life expectancy of less than 24 months due to non-cardiac conditions.~* Pregnant, or of childbearing potential and not on a reliable form of birth control.~* CRT-P, pacemaker, ICD or CRT-D device implanted previously, or currently.~* Restrictive, hypertrophic, or reversible cardiomyopathy.~* Mechanical right heart valve.~* Primary valvular disease and is indicated for valve repair or replacement.~* Heart transplant, or is currently on a heart transplant list.~* Significant renal dysfunction, as manifested by serum creatinine level \>2.5 mg/dl or ≥275 μmol/L or estimated glomerular filtration rate (GFR) ≤30 mL/min/1.73 m2, which is documented within the 30 days prior to enrollment or at baseline.~* Significant hepatic dysfunction, as evidenced by a hepatic function panel (serum) \> 3 times upper limit of normal, which is documented within the 30 days prior to enrollment or at baseline.~* Chronic or treatment-resistant severe anemia (hemoglobin \<10.0 g/dL), which is documented within the 30 days prior to enrollment or at baseline.~* On intravenous inotropic drug therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT-P ON (Type: ACTIVE_COMPARATOR): CRT-P Implant CRT-P ON
- CRT-P OFF (Type: PLACEBO_COMPARATOR): CRT-P Implant CRT-P OFF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues